DXCM

DexCom, Inc. (DXCM)

$55.15
*  
0.21
0.38%
Get DXCM Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading DXCM now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

DexCom, Inc. (DXCM)

Deutsche Bank dbAccess Health Care Conference Call

May 29, 2013 12:00 ET

Executives

Steve Pacelli - Executive Vice President, Strategy and Corporate Development

Analysts

Kristen Stewart - Deutsche Bank

Presentation

Kristen Stewart - Deutsche Bank

Alright. Thanks everybody for joining us for another session. My name is Kristen Stewart, the Medical Supplies and Devices analyst here at DB. I’m pleased to introduce Steve Pacelli from Dexcom. He is the Executive Vice President, Strategy and Corporate Development. The way we’re going to run this session is that he is going to give a brief overview just kind of on Dexcom, we are going to move into then some Q&A as a reminder you can raise your hand we’ll bring the mic to you if you would like to ask a question or you can also submit them through the Yorn app, the website address for that is yorn.com/db and it is anonymous so feel free to ask whatever questions you would like. So without further adieu I’d like to turn it over to Steve. Thanks again for coming.

Steve Pacelli - Executive Vice President, Strategy and Corporate Development

Great, thank you and good morning or good afternoon I guess welcome. I’m going to spend a few minutes as Kristen said introducing Dexcom and then be happy to field questions. So, before I do the quick obligatory Safe Harbor statement. I will be making some forward-looking statements today so please refer to our SEC filings; we’re not going to be updating these other than on quarterly and annual earnings calls. So as you all know diabetes is a global epidemic.

Just a short time ago, 20 years ago worldwide about 135 million people expected to have diabetes, about 10 years ago that number was pushing 200 million, today a staggering 366 million people worldwide are afflicted with diabetes. And then in the not too distant future 2030 it’s estimated that over half a billion people worldwide will be afflicted with diabetes. The U.S. is no different, not spared; everyday in the U.S. one in three children born will develop diabetes, everyday 5000 people will be diagnosed with diabetes, 55 people will go blind as a result of complications from diabetes, 230 amputations will be performed and 120 people will enter treatment for end-stage kidney failure.

But the most staggering statistic here is that one in 10 healthcare dollars today is spent treating either direct or indirect consequences associated with diabetes. So what’s the problem? To effectively treat diabetes you really need to know where you are going, you need to know the speed and direction of your blood sugar above all else, before you can effectively treat it, before you know how what tools whether you take insulin, whether you need to ingest carbohydrates, it’s really all about speed and direction of blood sugar. And so the management of diabetes is really the patients are trying to maintain a delicate balance between hyperglycemia or high blood sugar and hypoglycemia or low blood sugar. When patients are high or have hyperglycemia, they don’t really have symptoms, symptoms that they can feel, it’s really - but the high blood sugar really leads to all the chronic complications associated with diabetes, all the micro and macro-vascular damage that leads to cardiovascular disease, blindness, kidney failure, neuropathy, retinopathy. But it’s the time that patients spend lower hypoglycemic the patients actually fear the most because hypoglycemia has severely acute consequences associated with it.

Patients who go low start by experiencing maybe they start sweating, feel a little bit shaky, they start to experience diminished cognitive function and if not treated, if they don’t ingest carbohydrate the patients can drift off into a coma. This is when you hear about patients with diabetes who pass out while driving home from work and crash their car who have nocturnal hypoglycemia where they go low at night and if not treated these patients can actually drift into a coma and ultimately die. And so patients out of fear of hypoglycemia historically tend to ride relatively high with their blood sugars on average which of course as I just mentioned leads to all the chronic complications associated with the disease.

So today’s standard of care at the single-point finger stick it doesn’t tell the whole story, let me give you an example. This is a day in a life of a patient with Type 1 diabetes pretty typical patient on insulin would take somewhere between four to six finger sticks a day. So, this is a pretty typical patient here, takes a finger stick with their breakfast, takes a finger stick at lunch, at dinner and at bed time, just go and check their blood sugar. Well the finger stick companies would have us believe that you could connect these dots and somehow start to see a trend and understand what the patient’s blood sugar profile over the course of that 24-hour period was.

Unfortunately when you overlay Continuous Glucose Monitoring on top of it you see a much different picture, right. As patients trying that gray bar across the middle is the target range, patients trying to maintain their blood sugar within that target range and as you can see overlaying the benefits of Continuous Glucose Monitoring patient with above their target range for over 13 hours the patient had a dangerously low hypoglycemic episode for over an hour in the middle of the night and they spend above 210 milligrams per deciliter which is relatively elevated for almost five hours. So the solution for Dexcom peace of mind with a push of a button I’m going to play a short video to introduce you to our latest commercial product the G4 Platinum.

Read the rest of this transcript for free on seekingalpha.com